Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancer.

@article{Tsuchiya2011PharmacoeconomicAO,
  title={Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancer.},
  author={Takanori Tsuchiya and Takashi Fukuda and Masashi Furuiye and Koichi Kawabuchi},
  journal={Lung cancer},
  year={2011},
  volume={74 3},
  pages={521-8}
}
Prolongation of progression-free survival and overall survival have been reported with consolidation therapy after first-line chemotherapy in non-small cell lung cancer, but only a few pharmacoeconomic analyses have been performed. We performed a pharmacoeconomic analysis to assess the cost-effectiveness of consolidation therapy with pemetrexed compared with non-consolidation therapy. We developed a Markov model to evaluate the incremental cost-effectiveness ratio (ICER) of consolidation… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2010

American Society of Clinical Oncology guidance statement: the cost of cancer care.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2009

Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2009

Similar Papers

Loading similar papers…